EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation

Shushu Zhao, Yeqing Chen, Pratik S Bhojnagarwala, Cory Livingston, Joshua Jose, Yangcheng Gao, Daniel H Park, Meenhard Herlyn, David B Weiner

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-011073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Shushu Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Melanoma, Interleukin-13 Receptor alpha2 Subunit, T-Lymphocytes, Antibodies, Bispecific. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melanoma is a highly aggressive skin cancer, especially in advanced stages. While current treatments such as targeted therapies and immunotherapies have made significant progress, challenges like drug resistance and limited effectiveness in some patients persist. Therefore, ongoing development of novel therapies, particularly for late-stage melanoma, is crucial.

Methods

In this study, we explored the expression of interleukin-13 receptor subunit alpha-2 (IL13Rα2) in melanoma patient-derived xenograft models. We investigated IL13Rα2 as a potential target for melanoma treatment by employing an IL13Rα2-CD3 bispecific T-cell engager (BTE). We tested the effect of IL13Rα2-CD3 BTE on T cell activity by flow cytometry. We studied the potency of IL13Rα2-CD3 BTE in tumor killing assay in vitro. For in vivo studies, we administered DNA expression cassettes encoding IL13Rα2-CD3 BTE (IL13Rα2-CD3 DNA encoding BTE (dBTE)) into immunodeficient mice for direct in vivo expression. The mice were challenged with A375 cells and then treated with IL-13Rα2-CD3 dBTE versus control and reconstituted with human peripheral blood mononuclear cells (PBMCs) or T cells. Tumor development was monitored, and T cell infiltration in the tumor was analyzed throughflow cytometry.

Results

Our findings revealed heterogeneous expression of IL-13Rα2, particularly in samples from advanced stages of melanoma. The IL13Rα2-CD3 BTE facilitated T-cell activation and proliferation by bridging melanoma cells and T cells. We also observed the ability of IL13Rα2-CD3 BTE to direct T cells to kill multiple melanoma patient-derived cell lines through xCELLigence assay in vitro, including those with various mutations associated with late-stage metastatic melanoma. IL13Rα2-CD3 dBTE expressed in vivo led to notable tumor regression through inducing increased T-cell infiltration and activation within the tumor microenvironment.

Conclusions

These promising findings underscore the potential of targeting IL13Rα2 as a relevant target for the development of biologics including dBTE aimed at treating specific subsets of melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaInterleukin-13 Receptor alpha2 SubunitT-LymphocytesAntibodies, BispecificSkin NeoplasmsHumansAnimalsMiceXenograft Model Antitumor AssaysFemaleCell Line, TumorCD3 Complex

Stichwörter der Autor:innen

Bispecific T cell engager - BiTEImmunotherapyMelanoma

Substanzen

Interleukin-13 Receptor alpha2 SubunitAntibodies, BispecificIL13RA2 protein, humanCD3 Complex

Autor:innen und Institutionen

  • Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, USA.
  • University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, USA dweiner@wistar.org.

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • Fishman Family Foundation
  • NIH
  • WW Smith Charitable Trust
  • INOVIO Pharmaceuticals

Zitieren

APA

Zhao, S., Chen, Y., Bhojnagarwala, P. S., Livingston, C., Jose, J., Gao, Y., Park, D. H., Herlyn, M., & Weiner, D. B. (2025). Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-011073

Vancouver

Zhao S, Chen Y, Bhojnagarwala PS, Livingston C, Jose J, Gao Y, et al. Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-011073

BibTeX
@article{Zhao2025,
  author = {Zhao, Shushu and Chen, Yeqing and Bhojnagarwala, Pratik S and Livingston, Cory and Jose, Joshua and Gao, Yangcheng and Park, Daniel H and Herlyn, Meenhard and Weiner, David B},
  title = {Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-011073}
}
Kostenlos starten →